Recent experience with decitabine in MDS.
Kantarjian
Hagop M
HM
Chair, Leukemia Department, and Professor of Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
D000077209:Decitabine; D001374:Azacitidine